ArriVent BioPharma announced promising Phase 1 results for ARR-217, an antibody-drug conjugate targeting CDH17, in heavily pretreated gastrointestinal cancer patients. At a 6 mg/kg dose, the drug achieved a 44.8% objective response rate in colorectal cancer patients, with a manageable safety profile and no severe lung toxicity observed. These results support advancing ARR-217 into a Phase 1b dose optimization study, with further data expected in 2027. This progress marks a significant milestone for ArriVent's ADC pipeline and offers hope for patients with limited treatment options.
ArriVent's Phase 1 data for ARR-217 in gastrointestinal cancers provides context for health sector activity on Pluang. As of Oct 25, 2026 19:21 WIB, 44 of 150 health stocks rose while 105 fell. Notable movers include Inovio Pharmaceuticals Inc (INO) with a price of USD 0.90 and a 6.94% gain, Hims and Hers Health Inc (HIMS) down 4.87% at USD 27.71, and Amylx Pharmaceuticals Inc (AMLX) down 4.80% at USD 27.20.
Chery unveiled its Globalisation 3.0 strategy at the 2026 International User Summit, aiming to transform from a traditional automaker into a high-tech integrated ecosystem by 2035. The strategy emphasizes AI adoption, green technologies, and local ma...
Unfair Links, founded by Rollo Unden and Oliver Fish, has launched a beta service providing local backlinks that are matched to a business's Google Business Profile, country, language, and page topic. Unlike generic backlinks, these links come from r...
Tango, a global live-streaming platform, has donated tens of thousands of dollars to support FRIDA Ukraine's mobile cancer screening program. This initiative brings essential cancer detection and preventive healthcare services directly to underserved...
California's upcoming AI safety mandate, effective May 15, 2027, is creating tension with federal military cybersecurity rules under the Defense Federal Acquisition Regulation Supplement (DFARS). Veteran-led engineering groups have developed advanced...
Greg Abel highlighted that every one-point increase in BNSF's profit margin translates to about $230 million in additional cash flow for Berkshire Hathaway. This underscores the significant impact BNSF's operational efficiency has on Berkshire's over...
